


Stage IV lung carcinoma with *ALK* translocation



<sup>a</sup>ESMO-MCBS v1.1 score for new therapy/indication approved by the EMA since 1 January 2016. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.  
<sup>b</sup>Preferred option [203a].  
<sup>c</sup>Not EMA-approved.